Section of Pediatric Diabetes and Metabolism, Department of Surgery, Dentistry, Pediatrics, and Gynecology, University of Verona, Verona, Italy.
Department of Woman, Child and of General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.
Pediatr Obes. 2024 Dec;19(12):e13183. doi: 10.1111/ijpo.13183. Epub 2024 Oct 27.
The diagnosis of monogenic obesity is burdened by frequent variants of uncertain significance (VUS). We describe our real-life approach of variant reassessment over time and we assess whether inconclusive variants are decreasing in monogenic obesity.
We tested for monogenic obesity (genes: LEPR, POMC, ADCY3, PCSK1, CARTPT, SIM1, MRAP2, LEP, NTRK2, BDNF, KSR2, MAGEL2, SH2B1, MC4R, MC3R) in 101 children/adolescents (11.7 [7.3-13.7] years, 3.6 [3.3-4.0] z-BMI) in Verona and 183 (11.3 [8.4-12.2] years, 3.2 [2.7-3.9] z-BMI) in Naples from January 2020 to February 2023. In March-July 2024 we reassessed the baseline variants by updated software interpretation and literature renavigation.
We initially found 20 VUS, 4 Likely Pathogenic (LP), 5 Likely Benign (LB) and 1 benign variant in 33 individuals. At follow-up, 6 VUS were reclassified as benign/LB, one LP as pathogenic and 3 LB as benign. Overall, 10/30 variants (6/18 in Verona, 3/11 in Naples and a variant found in both centres) were reclassified, leading to a less uncertain report for 13 of 33 variant-carrying patients. Monogenic obesity was diagnosed in 3 probands in Verona and 4 in Naples, carrying variants at MC4R or NTRK2.
Our variant reassessment was effective to improve classification certainty for the 39% of patients and suggested that the molecular diagnosis of monogenic obesity is becoming more accurate over time.
单基因肥胖的诊断受到频繁出现的意义不确定变异(VUS)的困扰。我们描述了我们在实际工作中随时间对变异进行重新评估的方法,并评估了单基因肥胖症中不确定的变异是否在减少。
我们在 2020 年 1 月至 2023 年 2 月期间,在维罗纳检测了 101 名儿童/青少年(11.7 [7.3-13.7] 岁,3.6 [3.3-4.0] z-BMI)和那不勒斯的 183 名儿童/青少年(11.3 [8.4-12.2] 岁,3.2 [2.7-3.9] z-BMI)的 LEPR、POMC、ADCY3、PCSK1、CARTPT、SIM1、MRAP2、LEP、NTRK2、BDNF、KSR2、MAGEL2、SH2B1、MC4R、MC3R 等基因,以明确单基因肥胖。在 2024 年 3 月至 7 月,我们通过更新的软件解释和文献再分析,重新评估了基线变异。
我们最初在 33 名患者中发现了 20 个意义不确定变异、4 个可能致病性变异(LP)、5 个可能良性变异(LB)和 1 个良性变异。随访时,6 个意义不确定变异被重新分类为良性/LB,1 个 LP 被重新分类为致病性,3 个 LB 被重新分类为良性。总的来说,30 个变异中有 10 个(维罗纳的 6 个,那不勒斯的 3 个)被重新分类,导致 33 个携带变异的患者中有 13 个的报告不确定性降低。在维罗纳和那不勒斯,分别有 3 名和 4 名患者被诊断为单基因肥胖,携带 MC4R 或 NTRK2 变异。
我们的变异重新评估有效地提高了 39%患者的分类确定性,并表明单基因肥胖的分子诊断随着时间的推移变得更加准确。